References and Notes
1 For a recent review, see: Moulin A.
Bibian M.
Blayo
A.-L.
El Habnouni S.
Martinez J.
Fehrentz J.-A.
Chem. Rev.
2010,
110:
1809
2a
Patel NB.
Khan IH.
Rajani SD.
Eur. J. Med. Chem.
2010,
45:
4293
2b
Bayrak H.
Demirbas A.
Karaoglu
SA.
Demirbas N.
Eur. J.
Med. Chem.
2009,
44:
1057
2c
Isloor AM.
Kalluraya B.
Shetty P.
Eur. J. Med. Chem.
2009,
44:
3784
2d
Bayrak H.
Demirbas A.
Demirbas N.
Karaoglu SA.
Eur. J. Med. Chem.
2009,
44:
4362
3
Katica CR.
Vesna D.
Vlado K.
Dora GM.
Aleksandra B.
Molecules
2001,
6:
815
4a
Demirbas N.
Ugurluoglu R.
Demirbas A.
Bioorg. Med. Chem.
2002,
10:
3717
4b
Romagnoli R.
Baraldi
PG.
Cruz-Lopez O.
Cara CL.
Carrion MD.
Brancale A.
Hamel E.
Chen L.
Bortolozzi R.
Basso G.
Viola G.
J.
Med. Chem.
2010,
53:
4248
5
Abdel-Megeed AM.
Abdel-Rahman HM.
Alkaramany G.-ES.
El-Gendy MA.
Eur.
J. Med. Chem.
2009,
117
6
Alanine A.
Anselm L.
Steward L.
Thomi S.
Vifian W.
Groaning MD.
Bioorg. Med. Chem. Lett.
2004,
14:
817
7a
Mathew V.
Keshavayya J.
Vaidya VP.
Giles D.
Eur.
J. Med. Chem.
2007,
42:
823
7b
Farooqui M.
Bora R.
Patil CR.
Eur.
J. Med. Chem.
2009,
794
8
Borg S.
Vollinga RC.
Labarre M.
Payza K.
Terenius L.
Luthman K.
J. Med. Chem.
1999,
42:
4331
9a
Yeung K.-S.
Farkas ME.
Kadow JF.
Meanwell
NA.
Tetrahedron Lett.
2005,
46:
3429
9b
Amarasinghe KKD.
Maier MB.
Srivastavab A.
Graya JL.
Tetrahedron
Lett.
2006,
47:
3629
9c
Katritzky AR.
Khashab NM.
Kirichenko N.
Singh A.
J. Org. Chem.
2006,
71:
9051
9d
Bibian M.
Blayo A.-L.
Moulin A.
Martinez J.
Fehrentz J.-A.
Tetrahedron
Lett.
2010,
51:
2660
10a
Su Y.
Jiang Z.
Hong D.
Lu P.
Wang Y.
Lin X.
Tetrahedron
2010,
66:
2427
10b
Kurz T.
Lolak N.
Geffken D.
Tetrahedron
Lett.
2007,
48:
2733
10c
Yin P.
Ma W.-B.
Chen Y.
Huang W.-C.
Deng Y.
He L.
Org. Lett.
2009,
11:
5482
10d
Ueda S.
Nagasawa H.
J. Am. Chem. Soc.
2009,
131:
15080
10e
Wang Y.
Miller RL.
Sauer DR.
Djuric SW.
Org.
Lett.
2005,
7:
925
10f
Lin S.
Lang JrY.-iA.
Lovell MF.
Perkinson NA.
J.
Org. Chem.
1979,
44:
4160
10g
Saleem RSZ.
Tepe JJ.
J.
Org. Chem.
2010,
75:
4330
10h
Perez MA.
Dorado
CA.
Soto JL.
Synthesis
1983,
483
11a
Temple C.
Kussner CL.
Montgomery JA.
J.
Org. Chem.
1965,
30:
3601
11b
Temple C.
Kussner CL.
Montgomery JA.
J. Org. Chem.
1967,
32:
2241
11c
Okamura T.
Kurogi Y.
J. Med. Chem.
2002,
45:
3703
11d
Hosmane RS.
Lim BB.
Burnett FN.
J. Org. Chem.
1988,
53:
382
12a
Alves MJ.
Booth BL.
Freitas AP.
Proença MF.
J. Chem. Soc., Perkin Trans. 1
1992,
913
12b
Booth BL.
Dias AM.
Proença MF.
J. Chem. Soc., Perkin Trans. 1
1992,
2119
12c
Alves MJ.
Booth BL.
Proença MF.
J. Heterocycl. Chem.
1994,
31:
345
12d
Booth BL.
Coster RD.
Proença MF.
Synthesis
1988,
389
12e
Alves MJ.
Booth BL.
Carvalho MA.
Pritchar d RG.
Proença MF.
J. Heterocycl.
Chem.
1997,
739
12f
Al-Azmi A.
Booth BL.
Carpenter RA.
Carvalho MA.
Marrelec E.
Pritchard RG.
Proença MF.
J. Chem. Soc., Perkin Trans. 1
2001,
2532
12g
Booth BL.
Cabral IM.
Dias AM.
Freitas AP.
Matos-Beja AM.
Proença MF.
Ramos-Silva M.
J.
Chem. Soc., Perkin Trans. 1
2001,
1241
12h
Carvalho MA.
Esteves TM.
Proença MF.
Booth BL.
Org.
Biomol. Chem.
2004,
2:
1019
12i
Carvalho MA.
Álvares Y.
Zaki ME.
Proença MF.
Booth BL.
Org. Biomol. Chem.
2004,
2:
2340
13
Dias AM.
Cabral IM.
Vila-Chã AS.
Proença MF.
Synlett
2007,
1231
14
General Procedure
for the Synthesis of 1,2,4-Triazolones 3
Hydrazine
monohydrate (2.0 equiv) was added to a suspension of imidazole 2 (0.52-1.95 mmol) in DMF (for 3a and 3b, 2.0
mL) or EtOH (for 3c-f, 1.0-5.0 mL). The mixture was
stirred at r.t. for 5-30 min (for 3a,b and 3d-e), and at 0 ˚C for 40 min (for 3c and 3f). The
resulting suspension was filtered and washed with EtOH and Et2O
to give compounds 3 (78-99%).
The structure of the products was confirmed by elemental analysis, ¹H
NMR and ¹³C NMR spectroscopy.
5-[5-Amino-1-(4-methoxyphenyl)-1
H
-imidazol-4-yl]-2,4-dihydro-3
H
-1,2,4-triazol-3-one (3a)
Mp >316 ˚C
(dec.). ¹H NMR (300 MHz, DMSO-d
6): δ = 11.20
(s, 1 H), 7.42 (d, J = 8.7
Hz, 2 H), 7.39 (s, 1 H), 7.09 (d, J = 8.7
Hz, 2 H), 5.22 (s, 2 H), 3.81 (s, 3 H). ¹³C NMR
(75 MHz, DMSO-d
6): δ = 158.98,
155.64, 144.33, 137.91, 130.96, 127.36, 126.31, 114.85, 108.10,
55.52. Anal. Calcd for C12H12N6O2:
C, 52.94; H, 4.44; N, 30.87. Found: C, 52.75; H, 4.60; N, 30.88.
IR (mull): 3428, 3331, 3102, 1715 (CO), 1634 cm-¹.
15
General Procedure
for the Synthesis of 1,2,4-Oxadiazolones 4
A yellow
suspension of 2 (0.29-1.85 mmol)
in CH2Cl2 (for 4a,
15.0 mL) or in MeCN (for 4b-d, 3.0-5.0 mL) was added to a
solution of hydroxylamine hydrochloride (for 4a,
3.0 equiv; for 4b-d,
2.0 equiv; for 4c, 1.2 equiv) in aq 1 M
KOH (for 4a, 3.0 equiv) or to a solution
of Et3N (for 4b-d, 3.0 equiv) in MeCN. The mixture was
stirred at r.t., and after 29-72 h the starting material
was totally consumed. The light yellow solid was filtered and washed
with EtOH, MeCN, and Et2O to give compounds 4 in 17-99% yield. The structure
of the products was confirmed by elemental analysis, ¹H
NMR and ¹³C NMR spectroscopy.
3-[5-Amino-1-(4-methoxyphenyl)-1
H
-imidazol-4-yl]-1,2,4-oxadiazol-5
(4
H
)-one (4a)
Mp 261-264 ˚C. ¹H
NMR (300 MHz, DMSO-d
6): δ = 13.00-10.00
(br s, 1 H), 7.49 (s, 1 H), 7.42 (d, J = 8.7
Hz, 2 H), 7.11 (d, J = 8.7
Hz, 2 H), 5.46 (s, 2 H), 3.81 (s, 3 H). ¹³C
NMR (75 MHz, DMSO-d
6): δ = 159.54,
159.30, 155.30, 140.73, 132.66, 126.78, 126.75, 114.96, 103.15,
55.56. Anal. Calcd for C12H11N5O3:
C, 52.75; H, 4.06; N, 25.63. Found: C, 52.85; H, 4.13; N, 25.57.
IR (mull): 3414, 3317, 3128, 1787 (CO), 1633 cm-¹.
16
General Procedure
for the Synthesis of 5
A suspension of aminopiperidine
or 1-amino-4-metilpiperazine (1.2-1.3 equiv) and imidazole 2 (0.98-1.20 mmol) in CH2Cl2 (0.5
mL) or EtOH (2.0 mL) was stirred at r.t.. After 45-50 min
the yellow suspension evolved to a white solid precipitate that
was filtered and washed with EtOH and Et2O. The structure
of the products obtained was confirmed by elemental analysis, ¹H
NMR and ¹³C NMR spectroscopy.
Ethyl [5-Amino-1-(4-methoxyphenyl)-1
H
-imidazol-4-yl](piperidin-1-ylimino)methylcarbamate (5a)
Mp 165-166 ˚C. ¹H
NMR (300 MHz, DMSO-d
6): δ = 8.06 (s,
1 H), 7.38 (d, J = 8.7
Hz, 2 H) 7.38 (s, 1 H), 7.10 (d, J = 8.7
Hz, 2 H), 5.69 (br s, 2 H), 3.81 (s, 3 H), 3.98 (q, J = 7.2 Hz,
2 H), 2.50-3.50 (br s, 4 H), 1.50 (br s, 6 H), 1.20 (t, J = 7.2 Hz,
3 H). ¹³C NMR (75 MHz, DMSO-d
6): δ = 162.35,
159.04, 149.28, 141.60, 130.05, 59.95, 55.55, 55.03, 26.69, 25.27,
14.28. Anal. Calcd for C19H26N6O3:
C, 59.05; H, 6.78; N, 21.75. Found: C, 59.08; H, 6.68; N, 21.69. IR
(mull): 3359, 3287, 3162, 3112, 3066, 1698 (CO), 1618, 1571 cm-¹.
17
General Procedure
for the Synthesis of 6 and 7
Acetic or benzoic anhydride
(2.0 equiv) was added to a suspension of 1 (1.0-4.0
mmol) in MeCN (1.0-5.0 mL) at 0 ˚C, and the mixture
was stirred at r.t. until the starting material was totally consumed
(2-4 h). The bright yellow/orange solid was filtered
and washed with MeCN and Et2O to give compounds 6 and 7 in 13-99% yields.
The structure of the products was confirmed by elemental analysis, ¹H NMR
and ¹³C NMR spectroscopy.
5-Amino-1-(4′-fluorophenyl)-4-[(
N-
benzoyl)cyano-formimidoyl]-1
H
-imidazole (7,
R
¹
= 4-FC
6
H
4
, R
²
= Ph)
Mp 167-168 ˚C. ¹H
NMR (300 MHz, DMSO-d
6): δ = 8.34 (br
s, 2 H), 8.08 (d, J = 7.2
Hz, 2 H), 7.77 (s, 1 H), 7.64 (t, J = 7.2
Hz, 1 H), 7.55 (dd, J = 9.0,
4.8 Hz, 2 H), 7.54 (t, J = 7.2
Hz, 2 H), 7.44 (t, J = 9.0
Hz, 1 H). ¹³C NMR (75 MHz, DMSO-d
6): δ = 174.93,
160.06 (d, J = 243
Hz), 151.23, 138.60, 135.38, 134.74, 132.81, 131.57 (d, J = 3 Hz),
129.41, 128.51, 125.08 (d, J = 8
Hz), 122.51, 116.31 (d, J = 22
Hz), 112.14. Anal. Calcd for C12H11N5O3˙0.1H2O:
C, 64.51; H, 3.67; N, 20.90. Found: C, 64.40; H, 3.81; N, 20.86. IR
(mull): 3342, 2232 (CN), 1629, 1603, 1529 cm-¹.
18
General Procedure
for the Synthesis of 8 and 9
Hydrazine monohydrate
(2.0 or 1.2 equiv) was added to a suspension of imidazole 6 (0.78-1.36 mmol) or 7 in EtOH (1.5-2.0 mL) at 0 ˚C
leading to a homogeneous solution. After 5 min a white solid precipitated
out of solution and was filtered and washed with EtOH and Et2O.
The structure of the products was confirmed by elemental analysis, ¹H
NMR and ¹³C NMR spectroscopy.
Characterization of 1-Methyl-4-(5-methyl-4
H
-1,2,4-triazol-3-yl)-1
H
-imidazol-5-amine (8c)
Mp >233 ˚C
(dec.). ¹H NMR (300 MHz, DMSO-d
6): δ = 13.15
(br s, 1 H), 7.20 (s, 1 H), 5.51 (br s, 2 H), 3.44 (s, 3 H), 2.23
(s, 3 H). ¹³C NMR (75 MHz, DMSO-d
6): δ = 158.43,
152.03, 139.21, 141.98, 139.87, 131.61, 108.53, 29.76, 13.76. Anal.
Calcd for C8H9N5O˙0.1H2O:
C, 46.71; H, 5.71; N, 46.69. Found: C, 46.65; H, 5.86; N, 46.25.
IR (mull): 3354, 3276, 3170, 3104, 2725, 1616, 1571 cm-¹.
1-(4-Fluorophenyl)-4-(5-phenyl-4
H
-1,2,4-triazol-3-yl)-1
H
-imidazol-5-amine (9b)
Mp >250 ˚C
(dec.). ¹H NMR (300 MHz, DMSO-d
6): δ = 13.94
(br s, 1 H), 8.06 (dt, J = 6.6,
1.5 Hz, 2 H), 7.64 (dd, J = 9.0,
4.8 Hz, 2 H), 7.55 (s, 1 H) 7.43 (t, J = 9.0
Hz, 2 H), 7.48-7.40 (m, 3 H), 5.75 (br s, 2 H). ¹³C
NMR (75 MHz, DMSO-d
6): δ = 161.48
(d, J = 244
Hz), 160.16, 152.27, 138.98, 131.58, 131.15, 128.65, 128.58, 127.11
(d, J = 9 Hz),
125.76, 116.58 (d, J = 23
Hz), 108.89. Anal. Calcd for C17H13N6F˙0.1H2O:
C, 63.39; H, 4.13; N, 26.08. Found: C, 63.26; H, 4.18; N, 26.01.
IR (mull): 3407, 3276, 3318, 3127, 1634, 1603, 1518 cm-¹.